Jeffrey M. Ostrove

Jeffrey M. Ostrove is Independent Director of Locana, Inc. He is also co-founder, CEO and Director of GenStem Therapeutics, a San Diego based company working on lentiviral modified stem cell treatments for lysosomal storage and mitochondrial diseases. Previously, he was the CEO of Locana and AbVitro Inc., a therapeutic target discovery company based on Next Generation Sequencing. AbVitro was sold to Juno Therapeutics and now is part of Celgene. Prior to AbVitro, Dr. Ostrove was the founding President and Chief Executive Officer of Ceregene, Inc., a clinical stage gene therapy company developing treatments for neurodegenerative and ocular diseases such as Alzheimer’s, Parkinson’s disease, ALS and retinitis pigmentosa. Ceregene was sold to Sangamo BioSciences. Prior to joining Ceregene, Dr. Ostrove was Chief Operating Officer of NeuroVir Therapeutics, Inc. located in Vancouver, B.C. and San Diego, CA and he was instrumental in its merger with Medigene AG. Preceding NeuroVir (Medigene), Dr. Ostrove served as Senior Vice President and chief scientist of MAGENTA Corporation of Rockville, Maryland, a CDMO company he co-founded as a subsidiary of BioReliance, Inc., where he was also Vice President of Scientific Development. Dr. Ostrove also served on the staff of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health. Dr. Ostrove holds a PhD in Molecular Biology from the University of Florida College of Medicine, and completed his post-doctoral training at The Johns Hopkins University School of Medicine. Dr. Ostrove is also a past member of the board of directors of the Biotechnology Industry Organization (BIO).